伊布鲁替尼和维尼托克拉克斯联合治疗地幔细胞淋巴瘤:两个比一个好吗?
Jian Li1, Constatine S Tam1,2,3,4
1Clinical Haematology, Alfred Hospital, Melbourne, Victoria, Australia.
Expert review of hematology
|November 8, 2024
概括
易布鲁替尼和维尼托克拉克斯的组合显示出治疗复发性或耐火性地幔细胞淋巴瘤 (MCL) 的前景. 这种固定时间的治疗方法可能为患有这种具有挑战性的B细胞淋巴瘤的患者提供新的治疗选择.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 膜细胞淋巴瘤 (MCL) 是一种具有攻击性的非霍奇金B细胞淋巴瘤,使用标准化疗结果不佳.
- 易布鲁替尼是复发性或耐火性MCL的标准第二线治疗.
- 威尼托克拉克斯显示出活性,但其在易布鲁丁尼布后的疗效需要进一步研究.
研究的目的:
- 审查结合ibrutinib和venetoclax在复发性/耐药性MCL中的证据.
- 分析关于这种组合治疗的AIM和SYMPATICO研究中的数据.
主要方法:
- 对II期AIM研究的审查:ibrutinib,其次是ibrutinib加venetoclax.
- 对SYMPATICOIII期研究的审查:同时使用易布鲁替尼和维尼托克拉克斯,固定两年维尼托克拉克斯持续时间.
主要成果:
- 易布鲁替尼和维尼托克拉克斯的组合已在复发/耐药性MCL患者中显示出有效性.
- 这种组合表明了固定时间治疗策略的潜力.
- 可测量的残留疾病和分子数据可以指导停止治疗的决定.
结论:
- 易布鲁替尼和威尼托克拉克斯的联合治疗对复发性/耐药性MCL有效.
- 固定的治疗时间是管理MCL的潜在策略.
- 这种组合的最佳时间可能会随着对一线易布鲁替尼和CAR-T治疗的新数据的发展而变化.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142